Please login to the form below

Not currently logged in
Email:
Password:

President of Lilly Oncology resigns

John H Johnson, president of Lilly Oncology has resigned effective January 28, citing personal considerations

John H Johnson, senior vice president and president of Lilly Oncology has resigned effective January 28, citing personal considerations.

Johnson was previously CEO of ImClone Systems, and joined Lilly when it acquired the cancer-focused biotech company in 2008. Lilly has not yet named a successor to lead its oncology unit, but said it will do so in the coming weeks.

Lilly chairman, president and CEO John Lechleiter said in a statement that Johnson "has guided the Lilly Oncology pipeline to an all-time high – one of the largest clinical-stage pipelines of potential cancer medicines in the industry."

Lilly Oncology's portfolio of marketed drugs includes the non-small cell lung cancer treatment Alimta and the ovarian cancer therapy Gemzar. The company has also declared a commitment to developing personalised cancer medications.

Johnson became CEO of ImClone in 2007, leaving his post as company group chairman of Johnson & Johnson's worldwide biopharmaceuticals unit, where he had responsibility for that company's biotechnology, immunology and oncology commercial businesses.

The $6.5bn acquisition of ImClone was the largest in Lilly's history. The deal was driven in large part by Lilly's desire to add ImClone's targeted cancer therapy Erbitux (cetuximab) to its portfolio.

25th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics